NI-501; emapalumab, NI-501; emapalumab
NI-0501-14
Phase 3 small_molecule active
Quick answer
NI-501; emapalumab, NI-501; emapalumab for Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE). is a Phase 3 program (small_molecule) at Swedish Orphan Biovitrum International AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Swedish Orphan Biovitrum International AB
- Indication
- Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active